Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC By Ogkologos - August 31, 2026 75 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the third pre-specified interim analysis of the OlympiA study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Addressing Cancer Pain with Complementary Methods (Part 1) April 7, 2023 Cincinnati Police Are Wearing Pink Badges For Breast Cancer Awareness September 24, 2019 Fisioterapeutas en oncología October 12, 2021 Improving research with registered reports May 16, 2022 Load more HOT NEWS Targeting FGFR1 in Patients with Tumour-Induced Osteomalacia Survivorship and Immune Checkpoint Inhibitors EMA Recommends Extension of Indications for Pembrolizumab to Malignant Pleural Mesothelioma Olaparib Plus Bevacizumab Provides Clinically Meaningful OS Improvement for Newly Diagnosed...
